Previous clinical studies confirmed that a tumor antigen-derived peptide vaccine can induce T cell activation and promote the infiltration of CD4+ and CD8+ T cells to kill antigen-expressing tumor cells [23, 24]. This evidence concerns the gene CD8A and neoplasm.